| . | Control . | MDT . |
|---|---|---|
| Number | 54 | 53 |
| Median age in years (range) | 61 (38–76) | 60 (38–78) |
| Sex m:f | 35: 19 | 35: 18 |
| Histopathological cell type | ||
| Adenocarcinoma | 40 | 38 |
| Squamus cell carcinoma | 14 | 15 |
| Histopathological stage of cancer | ||
| I | 2 (4) | 2 (4) |
| II | 11 (20) | 11 (21) |
| III | 41 (76) | 37 (70) |
| Path. CR | 0 | 3 (6) |
| ASA Grade | ||
| I | 4 (7) | 3 (6) |
| II | 36 (67) | 25 (47) |
| III | 14 (26) | 25 (47)* |
| . | Control . | MDT . |
|---|---|---|
| Number | 54 | 53 |
| Median age in years (range) | 61 (38–76) | 60 (38–78) |
| Sex m:f | 35: 19 | 35: 18 |
| Histopathological cell type | ||
| Adenocarcinoma | 40 | 38 |
| Squamus cell carcinoma | 14 | 15 |
| Histopathological stage of cancer | ||
| I | 2 (4) | 2 (4) |
| II | 11 (20) | 11 (21) |
| III | 41 (76) | 37 (70) |
| Path. CR | 0 | 3 (6) |
| ASA Grade | ||
| I | 4 (7) | 3 (6) |
| II | 36 (67) | 25 (47) |
| III | 14 (26) | 25 (47)* |
Figures are numbers of patients (per cent in parentheses); MDT, multidisciplinary team; ASA, American Society of Anesthesiologists; Path. CR, complete pathological response to neoadjuvant chemoradiotherapy
χ2 = 5.211, DF = 1, P = 0.022
| . | Control . | MDT . |
|---|---|---|
| Number | 54 | 53 |
| Median age in years (range) | 61 (38–76) | 60 (38–78) |
| Sex m:f | 35: 19 | 35: 18 |
| Histopathological cell type | ||
| Adenocarcinoma | 40 | 38 |
| Squamus cell carcinoma | 14 | 15 |
| Histopathological stage of cancer | ||
| I | 2 (4) | 2 (4) |
| II | 11 (20) | 11 (21) |
| III | 41 (76) | 37 (70) |
| Path. CR | 0 | 3 (6) |
| ASA Grade | ||
| I | 4 (7) | 3 (6) |
| II | 36 (67) | 25 (47) |
| III | 14 (26) | 25 (47)* |
| . | Control . | MDT . |
|---|---|---|
| Number | 54 | 53 |
| Median age in years (range) | 61 (38–76) | 60 (38–78) |
| Sex m:f | 35: 19 | 35: 18 |
| Histopathological cell type | ||
| Adenocarcinoma | 40 | 38 |
| Squamus cell carcinoma | 14 | 15 |
| Histopathological stage of cancer | ||
| I | 2 (4) | 2 (4) |
| II | 11 (20) | 11 (21) |
| III | 41 (76) | 37 (70) |
| Path. CR | 0 | 3 (6) |
| ASA Grade | ||
| I | 4 (7) | 3 (6) |
| II | 36 (67) | 25 (47) |
| III | 14 (26) | 25 (47)* |
Figures are numbers of patients (per cent in parentheses); MDT, multidisciplinary team; ASA, American Society of Anesthesiologists; Path. CR, complete pathological response to neoadjuvant chemoradiotherapy
χ2 = 5.211, DF = 1, P = 0.022
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
